Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Apr;39(4):441–444. doi: 10.1038/bjc.1979.78

Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man.

H H Wan, N Thatcher, P W Mullen, G N Smith, P M Wilkinson
PMCID: PMC2009933  PMID: 444399

Abstract

Serial serum diphenylhydantoin and urinary 5-(p-hydroxphenyl)-5-phenylhydantoin concentrations were determined in 8 patients with malignant disease and 4 healthy volunteers on 2 separate occasions after an oral dose of diphenylhydantoin (500 mg). No significant difference was observed between metabolism before and 10 days after immunization with BCG or Corynebacterium parvum. Volunteers without intervening immunization similarly showed no difference.

Full text

PDF
441

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
  2. Brien J. F., Inaba T., Kalow W. Comparative drug elimination in man-diphenylhydantoin and amobarbital. Eur J Clin Pharmacol. 1975 Oct 10;9(1):79–83. doi: 10.1007/BF00613433. [DOI] [PubMed] [Google Scholar]
  3. Farquhar D., Loo T. L., Gutterman J. U., Hersh E. M., Luna M. A. Inhibition of drug-metabolizing enzymes in the rat after Bacillus Calmette-Guérin treatment. Biochem Pharmacol. 1976 Jul 1;25(13):1529–1535. doi: 10.1016/0006-2952(76)90072-1. [DOI] [PubMed] [Google Scholar]
  4. Gerber N., Wagner J. G. Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res Commun Chem Pathol Pharmacol. 1972 May;3(3):455–466. [PubMed] [Google Scholar]
  5. Kabra P. M., Marton L. J. High-pressure liquid-chromatographic determination of 5-(4-hydroxyphenyl)-5-phenylhydantoin in humanurine. Clin Chem. 1976 Oct;22(10):1672–1674. [PubMed] [Google Scholar]
  6. MacGee J. Rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography. Anal Chem. 1970 Mar;42(3):421–422. doi: 10.1021/ac60285a024. [DOI] [PubMed] [Google Scholar]
  7. Mosedale B., Smith M. A. Letter: Corynebacterium parvum and anaesthetics. Lancet. 1975 Jan 18;1(7899):168–168. doi: 10.1016/s0140-6736(75)91471-3. [DOI] [PubMed] [Google Scholar]
  8. Petruch F., Schüppel R. V., Steinhilber G. Effect of diphenylhydantoin on hepatic drug hydroxylation. Eur J Clin Pharmacol. 1974 Jul 26;7(4):281–285. doi: 10.1007/BF00560345. [DOI] [PubMed] [Google Scholar]
  9. Sorrell T. C., Forbes I. J., Burness F. R., Rischbieth R. H. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet. 1971 Dec 4;2(7736):1233–1235. doi: 10.1016/s0140-6736(71)90547-2. [DOI] [PubMed] [Google Scholar]
  10. Sorrell T. C., Forbes I. J. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clin Exp Immunol. 1975 May;20(2):273–285. [PMC free article] [PubMed] [Google Scholar]
  11. Soyka L. F., Hunt W. G., Knight S. E., Foster R. S., Jr Decreased liver and lung drug-metabolizing activity in mice treated with Corynebacterium parvum. Cancer Res. 1976 Dec;36(12):4425–4428. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES